PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects

Neuropharmacology

Volumn 39, Issue 7, 2000, Pages 1197-1210

  Akunne, H C ^a   Zoski, K T ^a   Davis, M D ^a   Cooke, L W ^a   Meltzer, L T ^a   Whetzel, S Z ^a   Shih, Y H ^a   Wustrow, D J ^a   Wise, L D ^a   MacKenzie, R G ^a   Georgic, L M ^a   Heffner, T G ^a   Pugsley, T A ^a  

^a PFIZER INC   (United States)

Author keywords

Agonist; Antipsychotic; Autoreceptor; DA receptors; Haloperidol; Thymidine uptake

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; 2 [4 [2 (4 PHENYL 1 PIPERAZINYL)ETHYL]CYCLOHEXYLAMINO]PYRIMIDINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; AUTORECEPTOR; BUTACLAMOL; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; IDAZOXAN; METHYSERGIDE; MUSCARINIC M1 RECEPTOR; N (2 CHLORO 6 METHYLERGOLIN 8ALPHA YL)PIVALAMIDE; NEUROLEPTIC AGENT; PHENTOLAMINE; PRAZOSIN; QUINPIROLE; RITANSERIN; ROXINDOLE; SEROTONIN 1A RECEPTOR; SPIPERONE; TALIPEXOLE; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN REGION; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; MALE; MITOGENESIS; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOGENIC AMINES; BRAIN CHEMISTRY; CELLS, CULTURED; CHO CELLS; CRICETINAE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ELECTROPHYSIOLOGY; HUMANS; MALE; MEMBRANES; NEOSTRIATUM; PIPERAZINES; PYRIMIDINES; RATS; RATS, LONG-EVANS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; SPIPERONE; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 0034017898     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00224-5     Document Type: Article

References (48)

1. 3 receptor agonist ligand, to CHO-K1 cells. Life Sci. 57:1995;1401-1410.
2. Auerbach S.B., Lundberg J.F., Hjorth S. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacol. 34:1995;89-96.
3. Berman K.F., Weinberger D.R. Functional localization in the brain in schizophrenia. Tasman A. American Psychiatric Press Review of Psychiatry 10 (24). 1991;959 APPA Press, Washington, DC.
4. 3H]SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 35:1984;1885-1893.
5. Borison R.L., Albrecht J.W., Diamond B.L. Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol. Bull. 26:1990;207-210.
6. 2 receptor mRNA. Brain Res. 564:1991;203-219.
7. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-253.
8. Broekkamp R.W., Cervo S.K., Berendsen H.H.G., Van Delft A.M.L. Effect of metergoline, fenfluramine and 8-OH-DPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch. Pharmacol. 338:1988;191-195.
9. Carlsson A. Dopamine receptor agonists: intrinsic activity versus state of receptors. J. Neural Transm. 57:1983;309-315.
10. Chio C.L., Drong R.F., Riley D.T., Gill G.S., Slightom J.L., Huff R.M. D4 Dopamine receptor-mediated signalling events determined in transfected Chinese hamster ovary cells. J. Biol. Chem. 269:1994;11813-11819.
11. 1A Partial Agonist and Potential Antipsychotic Agent. II. Preclinical Behavioral Effects. Neuropharmacol. 39:1999;1211-1221.
12. Coward D.M., Dixon A.K., Urwyler S., White T.G., Enz A., Karobath M., Sherman G. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J. Pharmacol. Exp. Ther. 252:1990;279-285.
13. DeVry J. 5-HT1A receptor agonists: recent development and controversial issues. Psychopharmacol. 121:1995;1-26.
14. Goldberg T.E., Torrey E.F., Gold J.M., Ragland J.D., Weinberger D.R. Learning and memory in monozygotic twins discordant for schizophrenia. Psychol. Med. 23:1993;71-85.
15. Grace A.A., Bunney B.S. Intracellular and extracellular recording electrophysiology of nigral dopaminergic neurons-1: Identification and characterization. Neuroscience. 10:1983;301-315.
16. Hey J.A., Del-Prado M., Cuss F.M., Egan R.W., Sherwood J., Lin C.C., Kreutner W. Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea pigs. Clinical and Experimental Allergy. 25:1995;974-984.
17. 1A agonist, 8-OH-DPAT, preferentially activates cell body autoreceptors in rat brain in vivo. Naunyn-Schmeidberg's Arch. Pharmacol. 338:1988;463-471.
18. Hollister L.E., Davis K.L., Berger P.A. Apomorphine in schizophrenia. Commun. Psychopharmacol. 4:1980;277-281.
19. Lahti A.C., Weiler M.A., Corey P.K., Lahti R.A., Carlsson A., Tamminga C.A. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol. Psychiatry. 43:1998;2-11.
20. 2 receptor binding sites. Mol. Pharmacol. 21:1982;301-314.
21. MacKenzie R.G., VanLeeuwen D., Pugsley T.A., Shih Y.-H., DeMattos S., Tang L., Todd R.D., O'Malley K.L. Characterization of the human D3 receptor expressed in transfected cell lines. Eur. J. Pharmacol. - Mol. Pharmacol. Section. 266:1994;79-85.
22. Megens A.A., Awouters H.P., Schotte F.H.L., Meert A., Dugovic C., Niemegeers C.J.E., Leysen J.E. Survey on the pharmacodynaics of the new antipsychotic risperidone. Psychopharmacology. 114:1994;9-23.
23. 3 receptors. Eur. J. Pharmacol. 249:1993;R5-R6.
24. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacol. 99:1989;S18-27.
25. Meltzer H.Y. Atypical antipsychotic drugs. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1277-1286 Raven Press Ltd, New York.
26. Meltzer L.T., Christoffersen C.L., Serpa K.A., Pugsley T.A., Razupour A., Heffner T.G. Lack of involvement of haloperidol-sensitive sigma binding sites in modulation of dopamine neuronal activity and induction of dystonias by antipsychotic drugs. Neuropharm. 31(9):1992;961-967.
27. Meltzer L.T., Christoffersen C.L., Corbin A.E., Ninteman F.W., Serpa K.A., Wise L.D., Heffner T.G. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II: Neurophysiological and behavioral effects. J. Pharmacol. Exp. Ther. 274:1995;912-920.
28. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 43:1991;587-604.
29. 1A receptors. J. Pharmacol. Exp. Ther. 273:1995;1418-1427.
30. Monsma F.J., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43:1993;320-327.
31. Munson P.J., Rodbard D. LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:1980;220-239.
32. Naber D., Gaussares C., Moeglen J.M., Tremmel L., Bailey P.E. THE SDZ HDC COLLABORATIVE STUDY GROUP: Efficacy and tolerability of SDZ HDC 912, a partial dopamine D2 agonist, in the treatment of schizophrenia. Meltzer H.Y. Novel Antipsychotic Drugs. 1992;99-107 Raven Press Ltd, New York.
33. Newman-Tancredi A., Chaput C., Verriele L., Milan M.J. Clozapine, is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacol. 35:1996;119-121.
34. 4 receptors. J. Pharmacol. Exp. Ther. 277:1996;186-192.
35. 1B binding sites in bovine brain. Brain Res. 344:1985;167-171.
36. Pugsley T.A., Davis M.D., Akunne H.C., Cooke L.W., Whetzel S.Z., MacKenzie R.G., Shih Y.-H., Van Leewuen D.H., Demattos S.B., Georgic L.M., Caprathe B.W., Wright J.L., Jaen J.C., Wise L.D., Heffner T.G. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I: Neurochemical effects. J. Pharmacol. Exp. Ther. 274:1995;898-911.
37. 3 agonist PD 128907. J. Pharmacol. Exp. Ther. 275:1995;1355-1366.
38. 1A receptor activation. Eur. J. Pharmacol. 338:1997;R3-R5.
39. Scatchard G. The attractions of proteins for small molecules and ions. Ann. N. Y. Acad. Sci. 51:1949;660-672.
40. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (Lond.). 261:1976;717-718.
41. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Trends In Pharmacol. Sci. 15:1994;264-270.
42. 2L chimeras (Cos-7 cells). Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 21:1997;153-167.
43. Taminga C.A., Gotts M.D., Thaker G.K., Alphs L.D., Foster N.L. Dopamine agonist treatment of schizophrenia with N-propyl-norapomorphine. Arch. Gen. Psyciatr. 43:1986;398-402.
44. Wadenberg M.L., Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J. Neural Transm. [GenSect]. 83:1991;43-53.
45. Wadenberg M.L., Cortizo L., Ahlenius S. Evidence for specific interactions between 5-HT1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharmacol. Biochem. Behav. 47:1994;509-513.
46. Walters J.R., Roth R.H. Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedebergs Arch. Pharmacol. 296:1976;4-14.
47. Waters N., Svensson K., Haadsma-Svensson S.R., Smith M.W., Carlsson A. The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity. J. Neural Transm. 94:1993;11-19.
48. Wustrow D., Belliotti T., Glase S., Ross-Kesten S., Johnson D., Colbry N., Rubin R., Blackburn A., Akunne H., Corbin A., Davis M., Georgic L., Whetzel S., Zoski K., Heffner T., Pugsley T., Wise L. Aminopyrimidines with high affinity for both Serotonin and Dopamine Receptors. J. Med. Chem. 41:1998;760-771.